ACELYRIN, Inc.
SLRNDelisted May 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962918
ACELYRIN, Inc. was delisted on May 21, 2025; its insiders filed their last Form 4 on May 23, 2025; 106 institutions reported holding it in 13F filings for Q1 2025, worth $182.6M in total; no superinvestor held it.
13F holders, Q4 2024
Institutional positions in ACELYRIN, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 126
- +5 vs. Q3 2024
- Shares held
- 88.0M
- +766.9K (+0.9%) vs. Q3 2024
- Total value
- $276.4M
- −$153.6M (−35.7%) vs. Q3 2024
- New holders
- 19
- 44 more added
- Sold out
- 14
- 40 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SLRN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 2 | $704 |
| Q1 2025 | 106 | $182.6M |
| Q4 2024 | 126 | $276.4M |
| Q3 2024 | 122 | $430.2M |
| Q2 2024 | 113 | $383.7M |
| Q1 2024 | 109 | $613.2M |
| Q4 2023 | 110 | $632.6M |
| Q3 2023 | 102 | $847.0M |
| Q2 2023 | 82 | $1.60B |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding ACELYRIN, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 618,127 | $1.94M | 0.00% | −232,534−27.3% | Reduced |
| Northern Trust Corp | 630,051 | $1.98M | 0.00% | +23,130+3.8% | Added |
| Jacobs Levy Equity Management, Inc | 662,981 | $2.08M | 0.01% | −663,410−50.0% | Reduced |
| Ikarian Capital, LLC | 676,608 | $2.12M | 0.61% | −466−0.1% | Reduced |
| Kynam Capital Management, LP | 847,366 | $2.66M | 0.18% | 00.0% | Unchanged |
| RTW Investments, LP | 978,310 | $3.07M | 0.05% | 00.0% | Unchanged |
| State Street Corp | 1,441,273 | $4.53M | 0.00% | +168,177+13.2% | Added |
| Alyeska Investment Group, L.P. | 1,515,878 | $4.76M | 0.02% | +1,515,878 | New |
| StemPoint Capital LP | 1,704,825 | $5.35M | 1.34% | +386,971+29.4% | Added |
| Geode Capital Management, LLC | 1,709,086 | $5.37M | 0.00% | +57,472+3.5% | Added |
| Siren, L.L.C. | 1,729,665 | $5.43M | 0.24% | 00.0% | Unchanged |
| Palo Alto Investors LP | 1,792,895 | $5.63M | 0.87% | 00.0% | Unchanged |
| Opaleye Management Inc. | 2,235,000 | $7.17M | 1.26% | +341,340+18.0% | Added |
| Morgan Stanley | 2,323,521 | $7.30M | 0.00% | +537,068+30.1% | Added |
| Samsara BioCapital, LLC | 2,523,022 | $7.92M | 1.09% | 00.0% | Unchanged |
| General Atlantic LLC | 2,695,327 | $8.46M | 0.30% | −194,341−6.7% | Reduced |
| Blue Owl Capital Holdings LP | 2,783,946 | $8.74M | 2.07% | −10,000−0.4% | Reduced |
| Tybourne Capital Management (HK) Ltd | 2,906,629 | $9.13M | 2.29% | 00.0% | Unchanged |
| venBio Partners LLC | 3,806,410 | $12.0M | 7.00% | −46,060−1.2% | Reduced |
| OrbiMed Advisors LLC | 4,001,711 | $12.6M | 0.26% | 00.0% | Unchanged |
| Vanguard Group Inc | 4,080,010 | $12.8M | 0.00% | +13,021+0.3% | Added |
| Citadel Advisors LLC | 4,211,916 | $13.2M | 0.01% | −2,311,390−35.4% | Reduced |
| Millennium Management LLC | 4,714,402 | $14.8M | 0.01% | −772,770−14.1% | Reduced |
| BlackRock, Inc. | 6,020,868 | $18.9M | 0.00% | +38,494+0.6% | Added |
| AyurMaya Capital Management Company, LP | 9,334,735 | $29.3M | 25.94% | 00.0% | Unchanged |
| T. Rowe Price Investment Management, Inc. | 12,872,124 | $40.4M | 0.02% | +2,440,278+23.4% | Added |
| Acuta Capital Partners, LLC | 0 | $0 | 0.00% | −364,000−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −357,094−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −250,300−100.0% | Sold out |
| Artia Global Partners LP | 0 | $0 | 0.00% | −93,114−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −83,345−100.0% | Sold out |
| Shay Capital LLC | 0 | $0 | 0.00% | −78,500−100.0% | Sold out |
| Polar Asset Management Partners Inc. | 0 | $0 | 0.00% | −71,700−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −43,868−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −19,252−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −16,854−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,080−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −185−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −114−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −102−100.0% | Sold out |
| AJOVista, LLC | – | – | – | – | Not filed |